重组人血管内皮抑制素联合放化疗治疗局部晚期头颈部鳞癌
Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma by Recombinant Human Vascular Endostatin Combined with Chemoradiotherapy
-
摘要: 目的 分析重组人血管内皮抑制素注射液 (恩度) 联合放化疗治疗局部晚期头颈部鳞癌的疗效及安全性.方法 收集自2011年7月至2014年6月云南省肿瘤医院收治的局部晚期头颈部鳞癌患者病例资料.放化疗联合恩度组 (恩度组) 有46例患者, 放化疗组 (对照组) 有45例患者.分析比较2组近期疗效及毒副反应比, 总生存率 (OS) 、无疾病进展期 (PFS) .采用美国华盛顿大学生活质量评估比较2组生活质量.结果 恩度组与对照组客观反应率分别为87.0%和75.6% (χ2=1.946, P>0.05) , 疾病控制率分别为97.8%和95.6% (χ2=0.368, P>0.05) .恩度组与对照组的中位PFS分别为18.7月和14.7月 (P<0.05) , 中位OS分别为26.8月和23.6月 (P>0.05) , 恩度组与对照组各项不良反应发生率相近.恩度组生活质量评估在心情、焦虑、总分方面高于对照组, 差异有统计学意义 (P<0.05) .结论 恩度联合放化疗治疗局部晚期头颈部鳞癌过程中, 在一定程度上增加疗效, 延长了无疾病进展期, 同时不增加不良反应发生率, 提高一定生活质量, 但对于患者的生存期获益仍需进一步研究.Abstract: Objective To analyze the therapeutic efficacy of chemoradiotherapy combined with recombinant human vascular endostatin (endostar) in the treatment of locally advanced head and neck squamous cell carcinoma.Methods From July 2011 to June 2014, data of the patients with locally advanced head and neck squamous cell carcinomas were collected, including 46 patients with chemoradiotherapy combined with endostar and 45 patients with chemoradiotherapy only and the two groups were divided: endostar groups (46 patients) and control group (45 patients) . Objective response rates, disease control rate, overall survival (OS) , and progress free survival (PFS) were compared. Quality of Life Questionnaire from University of Washington was applied to evaluate the life quality of the two groups. Results The objective response rate of endostar group and control group were 87.0% and 75.6% respectively (χ2=1.946, P>0.05) , disease control rate being 97.8% and 95.6% respectively (χ2=0.368, P>0.05) , the median PFS being 18.7 months and 14.7 months respectively (P<0.05) , and median OS being 26.8 months and 23.6 months respectively (P>0.05) . The adverse reaction rate were similar between the two groups. The scores of quality of life, including mood and anxiety domain and total score, in endostar group were higher than those in control group (P <0.05) . Conclusion Endostar combined with chemoradiotherapy can enhance the therapeutic effect of locally advanced head and neck squamous cell carcinoma, prolong free survival progress, improve the quality of life and does not increase adverse reaction rate. But the survival benefit for patients still needs further study.
-
Key words:
- Head and Neck Neoplasms /
- Angiogenesis Inhibitors /
- Endostatin
-
[1] [1]FERLAY J, SHIN H R, BRAY F, et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer, 2010, 127 (12) :2893-2917. [2] [2]SEIWERT T Y, SALAMA J K, VOKES E E.The chemoradiation paradigm in head and neck cancer[J].Nat Clin Pract Oncol, 2007, 4 (3) :156-171. [3]曹素杰, 张育红.头颈部鳞癌切除患者近期生活质量的影响因素[J].现代肿瘤医学, 2016, 24 (2) :219-221. [4] [4]FOLKMAN J.Tumor angiogenesis:Therapeutrc implication[J].N End J Med, 1971, 285 (21) :1182-1187. [5] [5]NEUCHRIST C, EROVIC B M, HANDISURYA A, et al.Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck[J].Laryngoscope, 2001, 111 (10) :1834-1841. [6] [6]NEUCHRIST C, EROVIC BM, HANDISURYA A, et al.Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck[J].Head Neck, 2003, 25 (6) :464-474. [7] [7]RIEDEL F, GOTTE K, LI M, et al.Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo[J].Int J Oncol, 2003, 23 (3) :577-583. [8] [8] KIM Y M, HWANG S, KIM Y M, et al.Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1[J].JBC, 2002, 277 (31) :27872-27879. [9] [9]WEN Y E, RANYI LIU, CHANGCHUAN PAN, et al.multicenter randomized phase 2 clinical trial of a recombinant human endostatin adenovirus in patients with advanced head and neck carcinoma[J].Mol Ther, 2014, 22 (6) :1221-1229. [10] [10]FURY M G, LEE N Y, SHERMAN E, et al.A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer[J].Cancer, 2012, 118 (20) :5008-5014. [11] [11]MA X, YAO Y, YUAN D, et al.Recombinant human endostatinendostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One, 2012, 7 (12) :e53449. [12]牛牛, 李宝兰, 刘朝阳, 等.重组人血管内皮抑制素联合贝伐珠单抗体内抑瘤作用的效果及分析[J].中国肺癌杂志, 2013, 16 (02) :61-66.
点击查看大图
计量
- 文章访问数: 1719
- HTML全文浏览量: 526
- PDF下载量: 61
- 被引次数: 0